… The role of taxanes in the treatment of breast cancer has evolved … of randomized phase II
and phase III trials that have evaluated the role of taxanes for the management of breast cancer. …

… This randomized phase III trial was designed to compare … breast cancer. Using US Food
and Drug Administration–approved doses and schedules for each agent, this phase III study has …

… and breast cancers. We report here on the results of a NCIC Clinical Trials Group randomized
phase II study of … , defined in earlier phase I studies, 14,15 in patients with advanced breast …

… This randomized phase II trial assessed tamoxifen plus placebo or the epidermal growth
factor receptor inhibitor gefitinib in estrogen receptor (ER)–positive metastatic breast cancer. …

… This study was one of four concurrent randomized phase II CCTG trials that evaluated
pelareorep in metastatic solid tumours: colorectal (CRC) (NCT01622543), non-small cell lung …

… Here we report the final results of a prospective, multicenter, randomized, open-label, phase
III trial designed to test the hypothesis that the PFS obtained with sunitinib plus docetaxel …

… To evaluate the contemporary role for HRQOL assessment in advanced breast cancer, we
searched PubMed for the main and companion papers reporting the results of phase III trials …

… As advanced/metastatic breast cancer accounts for the largest population of patients treated
… the previous randomized studies. However, patients with advanced/metastatic breast cancer …

… effects, with a total of three episodes of grade 3 leukopenia being reported. … study compare
with those of other phase II trials of weekly docetaxel in patients with metastatic breast cancer […

… ); (2) invasive lobular carcinoma; and (3) presence of extensive intraductal component (EIC)…
Phase III study. Based on the promising results of our phase I–II study [15], a phase III …